COMPARATIVE EFFECTIVENESS AND ECONOMIC EVALUATION OF THERAPIES IN ADVANCED NON-SMALL-CELL LUNG CANCER: A PRECISION MEDICINE PERSPECTIVE

COMPARATIVE EFFECTIVENESS AND ECONOMIC EVALUATION OF THERAPIES IN ADVANCED NON-SMALL-CELL LUNG CANCER: A PRECISION MEDICINE PERSPECTIVE

Ph.D

Saved in:

Bibliographic Details
Main Author:	TAN PUI SAN
Other Authors:	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format:	Theses and Dissertations
Language:	English
Published:	2016
Subjects:	comparative effectiveness, economic evaluation, therapies, advanced non-small-cell lung cancer, precision medicine
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/126124
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: A phase II study in Caucasian and Asian patients
by: Millward, M.J., et al.
Published: (2016)

Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse
by: Zee, Y.K., et al.
Published: (2014)

A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer
by: Soo, R.A., et al.
Published: (2011)

A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer
by: Soo, R.A., et al.
Published: (2014)

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
by: Ku, G.Y., et al.
Published: (2016)

The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
by: Cho, B.C., et al.
Published: (2014)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014)

Cost-utility analysis of Immuno-Oncotherapy in chemotherapy-pretreated, recurrent, non-small cell lung cancer in Thailand
by: Geater, Sarayut L.
Published: (2023)

Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: Results of a meta-analysis of randomized controlled trials
by: Soo, R.A., et al.
Published: (2014)

Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations
by: Haaland, B., et al.
Published: (2016)

NATURAL KILLER CELL BASED THERAPY FOR LUNG CANCER
by: AMIT JAIN
Published: (2022)

Comparison of clinical with pathological nodal staging from systematic mediastinal lymph node dissection in early resectable non-small cell lung cancer
by: Chong, C.F., et al.
Published: (2011)

Chemotherapy in non-small cell lung cancer: opportunities for advancement
by: Akhtari, M, et al.
Published: (2020)

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
by: Sundar, Raghav, et al.
Published: (2022)

A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
by: Ma, B., et al.
Published: (2011)

A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
by: Ma, B., et al.
Published: (2014)

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients
by: Soo, R.A., et al.
Published: (2011)

The Role of nitric oxide in apoptotic susceptibility of human lung cancer and normal lung cells
by: Pithi Chanvorachote
Published: (2008)

Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer
by: Chin, L.P., et al.
Published: (2014)

Theranostics application of tumor-initiating cell probe TiY in non-small cell lung cancer
by: Lee, Yong-An, et al.
Published: (2023)

Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: A Cancer Therapeutics Research Group study
by: Soo, R.A., et al.
Published: (2014)

Small in size, but large in action: Micrornas as potential modulators of pten in breast and lung cancers
by: Abadi, Asal Jalal, et al.
Published: (2022)

CLONAL ARCHITECTURE AND GENOMIC FEATURES OF SMOKING VERSUS NON-SMOKING ONCOGENE-DRIVEN NON-SMALL CELL LUNG CANCER IN EAST ASIA
by: HUANG, CHEN-YANG
Published: (2023)

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
by: Basu, B, et al.
Published: (2021)

Mediastinal re-staging of non small-cell lung cancer
by: Khoo, K.-L.
Published: (2016)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2014)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2011)

A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians
by: Peng, S., et al.
Published: (2021)

PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
by: Lee, Yi Fei, et al.
Published: (2024)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
by: Sudo, M., et al.
Published: (2014)

Non-invasive diagnosis of lung cancer based on CFD modeling and fractal analysis
by: Chen, Rou, et al.
Published: (2024)

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy
by: Soo, R.A., et al.
Published: (2014)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)

Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations
by: Tan, P.S, et al.
Published: (2020)

Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma
by: Lim, S.M., et al.
Published: (2014)

Symptom clusters and their influences on the functional status in advanced lung cancer patients receiving chemotherapy
by: Thidarat Khamboon
Published: (2023)

CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer
by: Ali, A., et al.
Published: (2022)

The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: A single South East Asian laboratory's analysis of 670 cases
by: Pang, B., et al.
Published: (2014)

Symptom clusters in Thai patients with advanced lung cancer
by: Noppamat Pudtong
Published: (2013)

THE ONCOGENIC ROLE OF TREFOIL FACTOR 3 (TFF3) IN NON-SMALL CELL LUNG CANCER (NSCLC)
by: ZHANG MENGYI
Published: (2019)